Abstract:Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline, memory impairment, and behavioral alterations. The N-methyl-D-aspartate (NMDA) receptor has emerged as a promising target for AD pharmacotherapy due to its role in the disease's pathogenesis. This study leverages advanced computational methods to screen 80 active constituents of Withania somnifera (Ashwagandha), a traditional herb known for its neuroprotective effects, against the NMDA receptor, using FDA-approved Ifenprodil as a reference. Our blind virtual screening results demonstrated that all tested compounds could bind to various domains of the NMDA receptor, with binding energies ranging from − 4.1 to -11.9 kcal/mol, compared to Ifenprodil's -7.8 kcal/mol. Binding preference analysis revealed 7 compounds bound to the A-chain, 37 to the B-chain, 7 to the C-chain, and 29 to the D-chain of the receptor. Notable binding was observed predominantly at the Amino Terminal Domain (ATD) core site, some at the ATD-Ligand Binding Domain (LBD) interface, and a few at the Transmembrane Domain (TMD). Particularly, 17alpha-hydroxywithanolide D, with a binding energy of -11.9 kcal/mol, emerged as a prime candidate for further investigation. Molecular dynamics simulations of this compound revealed key interactions, including direct hydrogen bonding with residues ASP165, ARG431, THR433, LYS466, and TYR476 on the D-chain, as well as additional hydrophobic and water-bridging interactions. These simulations highlighted the compound's influence on dynamic conformational states of the GluN1b-GluN2B receptor complex, modulating interactions between GluN1b Lys178 and GluN2B Asn184. Furthermore, the compound affected the distance between LBD heterodimers and the tension within the LBD-M30 linker, demonstrating its potential to modulate NMDA receptor activity. This comprehensive study not only underscores the therapeutic promise of Withania somnifera derivatives for AD but also provides a detailed molecular basis for their efficacy, offering valuable insights for targeted drug development and innovative therapeutic strategies against Alzheimer's disease.

Computational and Experimental Assessments of Magnolol as a Neuroprotective Agent and Utilization of UiO-66(Zr) as Its Drug Delivery System

Magnolol Protects Against Oxidative Stress-Mediated Neural Cell Damage by Modulating Mitochondrial Dysfunction and PI3K/Akt Signaling

The Neuropharmacological Effects of Magnolol and Honokiol: A Review of Signal Pathways and Molecular Mechanisms

Magnolol Ameliorates Behavioral Impairments and Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease

Effect of magnolol on cerebral injury and blood brain barrier dysfunction induced by ischemia-reperfusion in vivo and in vitro

Magnolol Attenuates the Locomotor Impairment, Cognitive Deficit, and Neuroinflammation in Alzheimer’s Disease Mice with Brain Insulin Resistance Via Up-Regulating Mir-200C

Neuroprotective Potency of Neolignans in Magnolia officinalis Cortex Against Brain Disorders

Design, Synthesis and Biological Evaluation of Novel Osthole-Based Derivatives As Potential Neuroprotective Agents

Compound from Magnolia Officinalis Ameliorates White Matter Injury by Promoting Oligodendrocyte Maturation in Chronic Cerebral Ischemia Models

Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids As Multitarget-Directed Ligands for Cognitive Improvement in A Rat Model of Neurodegeneration in Alzheimer'S Disease

Design, Synthesis and Evaluation of Novel Chloro- Oxime Derivatives for Neurodegenerative Diseases

Synthesis and Evaluation of Clioquinol-Rolipram/roflumilast Hybrids As Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease.

Magnolol treatment reversed the glial pathology in an unpredictable chronic mild stress-induced rat model of depression.

Antidepressant‐like Effect of Magnolol on BDNF Up‐regulation and Serotonergic System Activity in Unpredictable Chronic Mild Stress Treated Rats

Design, Synthesis and Biological Evaluation of Novel (e)‐hydroxystyryl Aralkyl Sulfones As Neuroprotective Agents

Design, Synthesis, and Biological Evaluation of Diosgenin-Indole Derivatives As Dual-Functional Agents for the Treatment of Alzheimer's Disease.

Synthesis and biological evaluation of novel 8- substituted sampangine derivatives as potent inhibitor of Zn2+-Aβ complex mediated toxicity, oxidative stress and inflammation

In-Silico discovery of 17alpha-hydroxywithanolide-D as potential neuroprotective allosteric modulator of NMDA receptor targeting Alzheimer's disease

Magnolol exhibits anti-inflammatory and neuroprotective effects in a rat model of intracerebral haemorrhage.

In silico Evaluation of the Feasibility of Magnolia officinalis Electronshuttling Compounds as Parkinson’s Disease Remedy

A Tailored Phytosomes Based Nose-to-brain Drug Delivery Strategy: Silver Bullet for Alzheimer's Disease